Editor Brian Harrod Provides Comprehensive up-to-date news coverage, with aggregated news from sources all over the world from the Roundup Newswires Network
A recent Vermont law, the first of its kind in the U.S., aims to peel back the curtain on the rather obfuscated drug market. The law instructs state officials to report up to 15 drugs that had price increases by at least 15 percent in the previous year, or 50 percent over the last half-decade, the Wall Street Journal reports .
For months, my office has heard from families concerned about their ability to afford a device they desperately need in the event that a loved one suffers a sudden allergic reaction. Parents should not have to worry about whether they can afford an EpiPen for their children.
The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers. "Price and access exist in a balance, and we believe we have struck that balance," Heather Bresch says in prepared testimony released by the House Oversight and Government Reform Committee ahead of her Wednesday appearance before the panel.
In this file photo, a pharmacist holds a package of EpiPens epinephrine auto-injector, a Mylan product, in Sacramento Mylan CEO Heather Bresch is defending the cost for life-saving EpiPens and is offering no suggestion that there are plans to lower prices. Bresch's prepared testimony was released by the House Oversight and Government Reform Committee ahead of her Sept.
EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. Mylan NL Chief Executive Officer Heather Bresch will appear at a Sept.
The controversy surrounding the skyrocketing costs of Mylan's EpiPens, medication that counteracts potentially deadly allergic reactions, is "a product of their own success," according to a Wall Street Journal reporter on the pharma beat. "For a long time, this wasn't a product that many people knew about or wanted and it's really a credit to Mylan for making it into a brand with a name that is as well-recognized and highly sought as Band-Aids," Jonathan Rockoff said on Friday's MetroNews "Talkline."
Democratic presidential candidate Hillary Clinton called on pharmaceutical company Mylan NV to voluntarily drop the price of its severe allergy treatment drug EpiPen, which has increased in price by more than 400 percent in the past decade. "That's outrageous - and it's just the latest troubling example of a company taking advantage of its consumers," Clinton said in a statement.
U.S. Sen. Joe Manchin remained mum Wednesday as a pharmaceutical company run by his daughter faced mounting criticism for hiking prices on life-saving allergy injection pens. The Democratic West Virginia senator's daughter, Heather Bresch, is CEO of Mylan, the manufacturer of EpiPens.
U.S. Presidential candidate Hillary Clinton took to Facebook today to say the makers of the EpiPen are gouging consumers. How EpiPen's maker raised prices, and hackles, so much Sky-high price hikes for EpiPen, the injected emergency medicine for severe allergic reactions to foods and bug bites, have made its maker the latest target for patients and politicians infuriated by soaring drug prices.
Following complaints from consumers that the company had hiked the price of the emergency auto-injector by $100 in recent months for no obvious reason, members of Congress are calling for an investigation. The prescription-only device, which delivers a rapid shot of epinephrine, a medication that can counteract a severe allergic reaction, is standard issue for millions of Americans.
A growing chorus is calling on the Mylan pharmaceutical company to justify its price hikes on EpiPens, a potentially life-saving medication for children and others facing fatal allergies that has little real competition. In 2007, a two-pack of the epinephrine-filled devices went for $56.64 wholesale, according to data gathered by Connecture, a health insurance data specialist.